1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Kringle Pharma, Inc.

Kringle Pharma, Inc.

TTSE:4884
610.00
JPY
-3.00
(-0.49%)
3.01BMarket Cap
Nov 11Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
423.44
69.76
80.69
12.85
12.51
10.55
- -
Basic EPS, GAAP
-84.67
-273.52
-106.7
-72.51
-68.33
-158.46
-118.21
-133.92
- -
Free Cash Flow per Basic Share
-265.5
-306.8
-132.63
-135.05
3.25
-127.84
-103.32
-110.46
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
142.13
59.32
599.97
578.17
518.38
366.11
309.55
186.56
128.18
Tangible Book Value per Share
142.13
59.32
599.97
578.17
518.38
366.11
309.55
186.56
128.18
Basic Weighted Avg Shares
1
1
1
4
5
5
6
7
7
Sales/Revenue/Turnover
- -
- -
468
290
392
69
80
72
- -
Operating Margin (%)
- -
- -
-36.7
-123.51
-108.76
-1,283.41
-1,021.87
-1,259.37
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-65
-302
-118
-301
-332
-854
-756
-916
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-25.2
-103.94
-84.69
-1,233.43
-945.12
-1,268.79
- -
Working Capital
520
218
2,190
2,507
3,045
2,409
2,628
1,946
1,554
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
518
216
2,189
2,506
2,789
2,022
2,108
1,309
948
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-82.21
-9.8
-12.83
-12.53
-35.51
-36.63
-53.62
- -

Capital Structure

JPY

•

in mil. unless spec.
Dec'24
Mar'24
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
7
7
Market Capitalization
4,736
3,432
3,010

Working Capital

JPY

•

in mil. unless spec.
Dec'24
Mar'24
Mar'26
Total Current Assets
2,844
2,911
1,964
Cash, Cash Equivalents & STI
2,341
2,490
1,588
Accounts Receivable, Net
25
- -
- -
Inventories
364
364
250
Total Current Liabilities
94
198
410
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.07%
-37.9%
Free Cash Flow
- -
-854.41%
14.31%
Net Income, GAAP
- -
66.57%
21.13%
Sales/Revenue/Turnover
- -
-15.87%
-9.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19
24
- -
- -
80
2025
- -
- -
- -
- -
72
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-29.53
-30.6
- -
- -
-118.21
2025
- -
- -
- -
- -
-133.92
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kiichi Adachi
Full Time Employees
17
Sector
Health technology
Industry
Biotechnology
Address
Nakanoshima Qross Research & Development Center Osaka Japan 530-0005
IPO Date
Dec 28, 2020
Website
kringle-pharma.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Kringle Pharma, Inc. (TSE: 4884) is a late clinical-stage biopharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of hepatocyte growth factor (HGF)-based regenerative pharmaceuticals for intractable diseases. The company develops recombinant human HGF protein drugs including KP-100IT (oremepermin alfa) for acute spinal cord injury in Phase III with topline data announced in February 2024 and marketing authorization application submitted in November 2024; HGF for vocal fold scar in ongoing Phase III; HGF for amyotrophic lateral sclerosis following Phase II completion; HGF for acute kidney injury post Phase I; and partner Claris Biotherapeutics' program for neurotrophic keratitis in Phase I/II, with additional basic research and joint academic programs targeting idiopathic osteonecrosis of the femoral head, idiopathic pulmonary fibrosis, peripheral neuropathy, chronic spinal cord injury, and combination therapies with iPS cells. Founded on December 21, 2001, and headquartered in Saito Bio Incubator, Ibaraki, Osaka, Japan, with an additional office in Nakanoshima, Osaka, Kringle Pharma operates mainly in Japan while pursuing global partnerships including capital and business alliances with TOHO HOLDINGS CO., LTD. and Maruishi Pharmaceutical Co., Ltd. for Japanese distribution of acute spinal cord injury drugs; a license and supply agreement with Claris Biotherapeutics, Inc. (US) renewed for production scale-up in September 2023; joint research agreements with Keio University School of Medicine since 2021 for spinal cord injury therapies, Kobe University in June 2025 for Peyronie's disease, Gifu University in April 2024 for femoral head necrosis, Kanazawa University in June 2024 for pulmonary fibrosis, and Keio University in November 2024 for spinal cord injury biomarkers; US orphan drug designation and FDA pre-IND meetings in 2023; and patent grants and applications including for nervous disease treatments in Europe and new manufacturing processes.